Edition:
United Kingdom

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

3.88USD
13 Sep 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$3.88
Open
$4.07
Day's High
$4.26
Day's Low
$3.83
Volume
1,083,365
Avg. Vol
1,832,007
52-wk High
$18.50
52-wk Low
$1.97

Latest Key Developments (Source: Significant Developments)

Perrigo Announces Patent Litigation Settlement For The Generic Version Of Nascobal Nasal Spray
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - Perrigo Company PLC ::PERRIGO ANNOUNCES PATENT LITIGATION SETTLEMENT FOR THE GENERIC VERSION OF NASCOBAL® NASAL SPRAY.PERRIGO COMPANY PLC - TERMS OF SETTLEMENT ARE CONFIDENTIAL.PERRIGO COMPANY - SETTLED HATCH-WAXMAN LITIGATION RELATING TO NASCOBAL (CYANOCOBALAMIN) NASAL SPRAY BROUGHT BY ENDO PHARMACEUTICALS.  Full Article

Akebia Therapeutics Announces Settlement Of Auryxia Patent Litigation With Par Pharmaceutical
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS® ANNOUNCES SETTLEMENT OF AURYXIA® PATENT LITIGATION WITH PAR PHARMACEUTICAL.AKEBIA THERAPEUTICS INC - KERYX BIOPHARMACEUTICALS AND ITS LICENSOR PANION & BF BIOTECH ENTERED INTO A SETTLEMENT AND LICENSE AGREEMENT.AKEBIA THERAPEUTICS INC - RESOLVES PATENT LITIGATION IN RESPONSE TO PAR'S ANDA SEEKING APPROVAL TO MARKET A GENERIC VERSION OF AURYXIA TABLETS.AKEBIA THERAPEUTICS - COS WILL GRANT PAR A LICENSE TO MARKET ITS GENERIC VERSION OF AURYXIA IN UNITED STATES BEGINNING ON MARCH 20, 2025 OR EARLIER.AKEBIA THERAPEUTICS INC - PARTIES WILL TERMINATE ALL ONGOING HATCH-WAXMAN LITIGATION BETWEEN KERYX AND PANION AND PAR.AKEBIA THERAPEUTICS INC - AGREEMENT IS CONFIDENTIAL AND SUBJECT TO REVIEW BY U.S. FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE.  Full Article

Endo International - Unit Par Pharmaceutical Priced $1.5 Billion Of 7.500% Senior Secured Notes Due 2027 At $1,000 Per $1,000 Principal Amount
Friday, 15 Mar 2019 

March 14 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR SECURED NOTES.ENDO INTERNATIONAL - UNIT PAR PHARMACEUTICAL PRICED $1.5 BILLION OF 7.500% SENIOR SECURED NOTES DUE 2027 AT $1,000 PER $1,000 PRINCIPAL AMOUNT.  Full Article

Endo International PLC Announces Debt Refinancing Transactions
Thursday, 14 Mar 2019 

March 14 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC ANNOUNCES DEBT REFINANCING TRANSACTIONS, INCLUDING CASH TENDER OFFERS AND CONSENT SOLICITATIONS FOR UP TO $1.0 BILLION AGGREGATE PURCHASE PRICE OF ITS OUTSTANDING SENIOR NOTES.ENDO INTERNATIONAL PLC ANNOUNCES DEBT REFINANCING TRANSACTIONS, INCLUDING CASH TENDER OFFERS AND CONSENT SOLICITATIONS FOR UP TO $1.0 BILLION AGGREGATE PURCHASE PRICE OF ITS OUTSTANDING SENIOR NOTES.ENDO INTERNATIONAL PLC - EACH OF TENDER OFFERS AND CONSENT SOLICITATIONS WILL EXPIRE ON APRIL 10, 2019.  Full Article

Endo International PLC Announces Proposed Private Offering Of Senior Secured Notes
Thursday, 14 Mar 2019 

March 14 (Reuters) - Endo International PLC ::ENDO INTERNATIONAL PLC ANNOUNCES PROPOSED PRIVATE OFFERING OF SENIOR SECURED NOTES.ENDO INTERNATIONAL - INTENDS TO USE PROCEEDS FROM PROPOSED OFFERING TO PURCHASE A PORTION OF ENDO'S OUTSTANDING SENIOR UNSECURED NOTES, OTHERS.  Full Article

Perrigo Confirms Patent Challenge For Generic Version Of Nascobal
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF NASCOBAL.PERRIGO COMPANY PLC - ENDO PHARMA INITIATED PATENT LITIGATION REGARDING PERRIGO'S PARAGRAPH IV ABBREVIATED NDP FOR CYANOCOBALAMIN NASAL SPRAY 500MCG.  Full Article

Endo Announces FDA Decision Not To Include Vasopressin On 503B Bulks List
Friday, 1 Mar 2019 

March 1 (Reuters) - Endo International PLC ::ENDO ANNOUNCES FDA DECISION NOT TO INCLUDE VASOPRESSIN ON 503B BULKS LIST.ENDO - ANTICIPATE DISCUSSING WITH FDA IMPACT OF DECISION NOT TO INCLUDE VASOPRESSIN ON 503B BULKS LIST ON CO'S PENDING LITIGATION IN NEAR FUTURE.  Full Article

Endo Agrees Not To Oppose Additional Stay Of FDA Litigation Following Restoration Of Government Appropriations
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Endo International PLC ::ENDO AGREES NOT TO OPPOSE ADDITIONAL STAY OF FDA LITIGATION FOLLOWING RESTORATION OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL - U.S. FDA HAS REQUESTED A FURTHER STAY OF ENDO'S ONGOING LITIGATION AGAINST FDA THROUGH MARCH 15, 2019.  Full Article

Endo Agrees Not To Oppose Additional Stay Of FDA Litigation Following Restoration Of Govt Appropriations
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Endo International PLC ::ENDO AGREES NOT TO OPPOSE ADDITIONAL STAY OF FDA LITIGATION FOLLOWING RESTORATION OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL PLC - FDA REQUESTED A FURTHER STAY OF ENDO'S ONGOING LITIGATION AGAINST FDA THROUGH MARCH 15, 2019.ENDO INTERNATIONAL - IN STAY MOTION FDA "EXPECTS TO PUBLISH FINAL CLINICAL NEED DETERMINATION FOR VASOPRESSIN ON OR BEFORE MARCH 15, 2019.".  Full Article

Endo Anticipates Further Stay Of Compounding Litigation Due To Lapse Of Govt Appropriations
Monday, 31 Dec 2018 

Dec 31 (Reuters) - Endo International PLC ::ENDO ANNOUNCES ANTICIPATED FURTHER STAY OF COMPOUNDING LITIGATION DUE TO LAPSE OF GOVERNMENT APPROPRIATIONS.ENDO INTERNATIONAL PLC - FDA FILED A MOTION, SEEKING A FURTHER STAY OF SUIT FOR PERIOD OF TIME IN WHICH GOVERNMENT LACKS APPROPRIATIONS.ENDO INTERNATIONAL PLC - ENDO, OTHER INTERESTED PARTIES HAVE SUBMITTED COMMENTS ON FDA'S PROPOSED VASOPRESSIN DETERMINATION.ENDO INTERNATIONAL - IN LIGHT OF APPROPRIATIONS LAPSE, PROPOSED VASOPRESSIN DETERMINATION WILL NOW NOT OCCUR BY DEC 31, 2018.ENDO INTERNATIONAL PLC - IF FDA'S MOTION IS GRANTED, LITIGATION WILL BE STAYED FOR AS LONG AS APPROPRIATIONS LAPSE CONTINUES.ENDO INTERNATIONAL PLC - IS NOT AT THIS TIME AWARE WHEN APPROPRIATIONS MAY RESUME.  Full Article

UPDATE 1-U.S. judge allows public nuisance claim in opioid trial

Sept 9 The U.S. judge overseeing nationwide litigation concerning the opioid epidemic on Monday rejected Purdue Pharma LP's effort to dismiss claims that its activities caused a public nuisance.